Executive Summary
HHS awarded $1.26B across 7 contracts, with 57% bullish signals concentrated in CMS-driven cybersecurity, IT development, and Medicare communications, signaling robust near-term revenue for service providers. Recent awards (2024) show rapid outlays averaging 60% of obligations, indicating execution momentum and $800M+ in unexercised options for upside.
Neutral signals from nonprofits and matured contracts limit broad equity plays, prioritizing small/disadvantaged businesses in health IT and R&D.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior All HHS Contracts digest from March 12, 2026.
Investment Signals (4)
- CMS Cybersecurity & IT Surge (HIGH)▲
Three 2024 CMS awards totaling $245M obligated ($53M outlayed) to Iron Vine, Sparksoft, and Porter Novelli highlight accelerating spend on cyber ops, provider screening IT, and Medicare outreach.
- NIH Clinical R&D Momentum (MEDIUM)▲
$73M obligated ($36M outlayed) since April 2024 to Technical Resources signals sustained NIAID funding for clinical ops, with $337M options ceiling.
- BARDA Nonprofit R&D Lock-in (HIGH)▲
$724M 7-year biotech R&D obligation to nonprofit Advanced Technology International provides stability but no equity upside.
- Low Outlay Exposure (HIGH)▲
Average 30% outlay rate across contracts (e.g., 3% on $724M BARDA, 7% on $108M KARNA) flags potential funding delays.
Risk Flags (3)
- Execution [HIGH RISK]▼
Firm fixed price structures on 57% of value ($723M+ BARDA, $102M Iron Vine, $70M Sparksoft) risk cost overruns over multi-year terms.
- Execution [MEDIUM RISK]▼
Cost-plus-fixed-fee and time/materials pricing (KARNA, Technical Resources, Health Care Service, Porter Novelli) invite audits on allowable costs/labor hours.
- Market [MEDIUM RISK]▼
Nonprofit recipients (Advanced Tech, Health Care Service) capture 63% of value, muting investor upside.
Opportunities (3)
- ◆
$800M+ unexercised options across contracts (e.g., $265M Technical Resources ceiling, $87M Iron Vine) tied to performance milestones.
- ◆
Small/8(a)/women-owned firms (Karna, Sparksoft, Technical Resources) win 32% of value ($251M) via set-asides, positioning for HHS follow-ons.
- ◆
Rapid 2024 outlays (60% average on recent awards) signal cash flow ramps for CMS/IT players amid Medicare expansion.
Sector Themes (2)
- ◆
CMS dominates 44% of value ($357M) with cyber/IT/comms awards to for-profits, rapid outlays post-2024 awards.
- ◆
BARDA/NIH/IHS fund $866M in R&D/services, but nonprofits take 79% ($793M), favoring service subcontractors.
Watch List (3)
- 👁
{"entity"=>"Technical Resources International", "reason"=>"$337M options ceiling on $73M obligated NIAID clinical R&D, 50% outlayed in <1 year.", "trigger"=>"options exercised toward 2031 extension"}
- 👁
{"entity"=>"Iron Vine Security", "reason"=>"$189M ceiling cyber ops for CMS with $87M unobligated options to 2029.", "trigger"=>"outlays exceed $75M (75% of obligation)"}
- 👁
{"entity"=>"CMS 8(a) Pipeline", "reason"=>"Sparksoft/Porter wins signal set-aside momentum in IT/outreach.", "trigger"=>"new APS/CCICOPS-like awards >$50M"}
Get daily alerts with 4 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 7 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: All HHS Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals